Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0646 + Pemetrexed/Cisplatin in Advanced Non-Squamous NSCLC
NCT00799240Phase 2Completed
- Sponsor
- University of Kansas
- Start
- Jun 2009
- Primary completion
- Feb 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of dalotuzumab in non-small cell lung cancer (NSCLC), sponsored by University of Kansas. Started Jun 2009; status: completed.
02
Drugs
dalotuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00799240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00799240.